<p>SG Americas Securities LLC 在第二季度根据最新提交给证券交易委员会（SEC）的 13F 申报文件，将其在 Rhythm Pharmaceuticals, Inc.（NASDAQ: RYTM - 免费报告）的持股增加了 348.9%。该基金在该期间购买了额外的 26,214 股，持有公司股票 33,727 股。根据最新的 SEC 申报，SG Americas Securities LLC 持有的 Rhythm Pharmaceuticals 股份价值 1,385,000 美元，占公司价值的 0.06%。</p>
<p>获取 <strong>Rhythm Pharmaceuticals</strong> 警报：</p>
<ul>
<li>7 支将推动减肥药市场的股票</li>
</ul>
<p>许多其他机构投资者和对冲基金最近也买入和卖出了该股。Perceptive Advisors LLC 在第四季度将其在 Rhythm Pharmaceuticals 的持仓增加了 465.6%。Perceptive Advisors LLC 现在拥有公司股票 2,154,110 股，价值 99,024,000 美元，比上一季度增加了 1,773,282 股。安大略医疗养老金信托基金在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 381.2%。安大略医疗养老金信托基金现在拥有公司股票 730,643 股，价值 31,659,000 美元，比上一季度增加了 578,800 股。加拿大养老金计划投资委员会在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 116.1%。加拿大养老金计划投资委员会现在拥有公司股票 577,000 股，价值 25,001,000 美元，比上一季度增加了 310,000 股。Artisan Partners Limited Partnership 在第四季度购入了 Rhythm Pharmaceuticals 的新股份，价值约 12,477,000 美元。最后，Vanguard Group Inc.在第四季度将其在 Rhythm Pharmaceuticals 的持股增加了 7.0%。Vanguard Group Inc.现在拥有公司股票 3,226,938 股，价值 148,342,000 美元，比上一季度增加了 212,370 股。</p>
<h2>Rhythm Pharmaceuticals 股价表现</h2>
<p>NASDAQ RYTM 周五开盘价为 46.70 美元。公司的 50 天简单移动平均线为 44.81 美元，200 天简单移动平均线为 42.84 美元。该公司的市值为 28.5 亿美元，市盈率为-10.09，贝塔系数为 2.04。Rhythm Pharmaceuticals, Inc.的一年最低价为 20.97 美元，最高价为 53.92 美元。</p>
<ul>
<li>2 家有前景的减肥药生物技术公司</li>
</ul>
<p>Rhythm Pharmaceuticals（NASDAQ: RYTM - 获取免费报告）于 8 月 6 日星期二发布了季度财报。公司报告该季度每股亏损（EPS）为（0.55）美元，超过了每股（EPS）为（0.71）美元的共识预期 0.16 美元。Rhythm Pharmaceuticals 的净利润率为-254.88%，净资产收益率为-221.65%。该季度公司营收为 2908 万美元，高于共识预期的 2879 万美元。与去年同期相比，Rhythm Pharmaceuticals 的季度营收增长了 51.3%。平均而言，股票研究分析师预计 Rhythm Pharmaceuticals, Inc.在本财年将实现-4.4 美元的每股收益。</p>
<h2>Rhythm Pharmaceuticals 内部交易活动</h2>
<p>根据其他 Rhythm Pharmaceuticals 的消息，内部人员 Joseph Shulman 于 7 月 16 日星期二出售了 10,468 股公司股票。这些股票的平均价格为 53.00 美元，总交易额为 554,804.00 美元。交易完成后，该内部人员在公司持有 30 股，价值 1,590 美元。该交易已在 SEC 的法律文件中披露，可在 SEC 网站上找到。此外，内部人员 Joseph Shulman 于 7 月 16 日星期二又以每股 53.00 美元的平均价格出售了 10,468 股 Rhythm Pharmaceuticals 股票，总交易额为 554,804.00 美元。交易完成后，该内部人员在公司持有 30 股，价值 1,590 美元。该交易已在证券交易委员会的法律文件中披露，可在 SEC 网站上找到。此外，内部人员 Pamela J. Cramer 于 7 月 29 日星期一以每股 49.06 美元的平均价格出售了公司股票 1,395 股，总交易额为 68,438.70 美元。交易完成后，该内部人员在公司持有 31,735 股公司股票，价值 1,556,919.10 美元。过去三个月，内部人员共出售了价值 3,101,567 美元的 66182 股公司股票。公司内部人员持有公司股票的比例为 5.60%。</p>
<h2>华尔街分析师的观点</h2>
<p>一些分析师对该股发表了评论。Needham &amp; Company LLC 在 8 月 7 日星期三的研究报告中重申了对 Rhythm Pharmaceuticals 股票的 “买入” 评级，并给出了 55.00 美元的目标价。富国银行在 4 月 18 日星期四的研究报告中将 Rhythm Pharmaceuticals 的目标价从 53.00 美元降至 52.00 美元，并给予该公司 “超重” 评级。美国银行将 Rhythm Pharmaceuticals 的评级从 “买入” 调降至 “中性”，并将股票的价格目标从 49.00 美元降至 42.00 美元。最后，Canaccord Genuity Group 将 Rhythm Pharmaceuticals 的目标股价从 80.00 美元降至 79.00 美元，并给予该公司 “买入” 评级。一位研究分析师对该股给予持有评级，五位分析师给予买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “中等买入”，共识目标股价为 55.83 美元。</p>
<p><strong>查看我们关于 RYTM 的最新研究报告</strong></p>
<h2>Rhythm Pharmaceuticals 公司简介（免费报告）</h2>
<p>Rhythm Pharmaceuticals, Inc.是一家专注于罕见神经内分泌疾病的商业阶段生物制药公司。该公司的主力产品候选药是 IMCIVREE（setmelanotide），用于治疗 POMC、PCSK1、LEPR 缺陷性肥胖以及 Bardet-Biedl 综合征和 Alström 综合征。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比 Rhythm Pharmaceuticals 更喜欢的股票</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>迈克尔·伯里的阿里巴巴赌注及更广泛的市场影响</li>
<li>如何投资 FAANG 股票</li>
<li>杰夫·布朗的 Exegesis AI 股票推荐</li>
<li>对投资者最重要的沃伦·巴菲特股票：他自己的</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔·哈撒韦购买了奥尔特股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 2024 年的科技恐慌：亿万富翁知道的你不知道的（来自 InvestorPlace）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5"/></p>
<h2>现在是否值得投资 1,000 美元购买 Rhythm Pharmaceuticals？</h2>
<p>在考虑 Rhythm Pharmaceuticals 之前，您需要听到这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Rhythm Pharmaceuticals 并不在其中。</p>
<p>尽管 Rhythm Pharmaceuticals 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RYTM

<p>SG Americas Securities LLC 在第二季度增持了 Rhythm Pharmaceuticals, Inc.（纳斯达克股票代码：RYTM）348.9%，增持了 26,214 股。这使其持股总数达到 33,727 股，价值约为$385,000。其他机构投资者，包括 Perceptive Advisors LLC、安大略医疗养老金计划信托基金和加拿大养老金计划投资委员会，也大幅增加了对 Rhythm Pharmaceuticals 的持股。该公司的股票表现、季度收益和内部交易受到关注，显示出分析师建议关注生物技术行业未来发展的混合前景</p>

<p>SG Americas Securities LLC increased its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 348.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,727 shares of the company's stock after purchasing an additional 26,214 shares during the period. SG Americas Securities LLC owned 0.06% of Rhythm Pharmaceuticals worth $1,385,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>SG Americas Securities LLC 在第二季度根据最新提交给证券交易委员会（SEC）的 13F 申报文件，将其在 Rhythm Pharmaceuticals, Inc.（NASDAQ: RYTM - 免费报告）的持股增加了 348.9%。该基金在该期间购买了额外的 26,214 股，持有公司股票 33,727 股。根据最新的 SEC 申报，SG Americas Securities LLC 持有的 Rhythm Pharmaceuticals 股份价值 1,385,000 美元，占公司价值的 0.06%。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Rhythm Pharmaceuticals</strong> 警报：</p>
<ul>
<li>7 支将推动减肥药市场的股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Perceptive Advisors LLC lifted its position in shares of Rhythm Pharmaceuticals by 465.6% in the fourth quarter. Perceptive Advisors LLC now owns 2,154,110 shares of the company's stock valued at $99,024,000 after acquiring an additional 1,773,282 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Rhythm Pharmaceuticals by 381.2% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 730,643 shares of the company's stock valued at $31,659,000 after purchasing an additional 578,800 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Rhythm Pharmaceuticals by 116.1% during the 1st quarter. Canada Pension Plan Investment Board now owns 577,000 shares of the company's stock worth $25,001,000 after purchasing an additional 310,000 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter worth about $12,477,000. Finally, Vanguard Group Inc. raised its position in shares of Rhythm Pharmaceuticals by 7.0% in the fourth quarter. Vanguard Group Inc. now owns 3,226,938 shares of the company's stock valued at $148,342,000 after buying an additional 212,370 shares during the last quarter.</p>
<div class="lb-trans"><p>许多其他机构投资者和对冲基金最近也买入和卖出了该股。Perceptive Advisors LLC 在第四季度将其在 Rhythm Pharmaceuticals 的持仓增加了 465.6%。Perceptive Advisors LLC 现在拥有公司股票 2,154,110 股，价值 99,024,000 美元，比上一季度增加了 1,773,282 股。安大略医疗养老金信托基金在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 381.2%。安大略医疗养老金信托基金现在拥有公司股票 730,643 股，价值 31,659,000 美元，比上一季度增加了 578,800 股。加拿大养老金计划投资委员会在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 116.1%。加拿大养老金计划投资委员会现在拥有公司股票 577,000 股，价值 25,001,000 美元，比上一季度增加了 310,000 股。Artisan Partners Limited Partnership 在第四季度购入了 Rhythm Pharmaceuticals 的新股份，价值约 12,477,000 美元。最后，Vanguard Group Inc.在第四季度将其在 Rhythm Pharmaceuticals 的持股增加了 7.0%。Vanguard Group Inc.现在拥有公司股票 3,226,938 股，价值 148,342,000 美元，比上一季度增加了 212,370 股。</p>
</div><h2>Rhythm Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 股价表现</h2>
</div><p>NASDAQ RYTM opened at $46.70 on Friday. The business's 50-day simple moving average is $44.81 and its 200-day simple moving average is $42.84. The firm has a market capitalization of $2.85 billion, a P/E ratio of -10.09 and a beta of 2.04. Rhythm Pharmaceuticals, Inc. has a 1-year low of $20.97 and a 1-year high of $53.92.</p>
<ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><p>NASDAQ RYTM 周五开盘价为 46.70 美元。公司的 50 天简单移动平均线为 44.81 美元，200 天简单移动平均线为 42.84 美元。该公司的市值为 28.5 亿美元，市盈率为-10.09，贝塔系数为 2.04。Rhythm Pharmaceuticals, Inc.的一年最低价为 20.97 美元，最高价为 53.92 美元。</p>
<ul>
<li>2 家有前景的减肥药生物技术公司</li>
</ul>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.16. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The company had revenue of $29.08 million during the quarter, compared to the consensus estimate of $28.79 million. During the same period in the previous year, the firm earned ($0.82) earnings per share. Rhythm Pharmaceuticals's revenue for the quarter was up 51.3% on a year-over-year basis. On average, equities research analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.4 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（NASDAQ: RYTM - 获取免费报告）于 8 月 6 日星期二发布了季度财报。公司报告该季度每股亏损（EPS）为（0.55）美元，超过了每股（EPS）为（0.71）美元的共识预期 0.16 美元。Rhythm Pharmaceuticals 的净利润率为-254.88%，净资产收益率为-221.65%。该季度公司营收为 2908 万美元，高于共识预期的 2879 万美元。与去年同期相比，Rhythm Pharmaceuticals 的季度营收增长了 51.3%。平均而言，股票研究分析师预计 Rhythm Pharmaceuticals, Inc.在本财年将实现-4.4 美元的每股收益。</p>
</div><h2>Insider Activity at Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 内部交易活动</h2>
</div><p>In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 10,468 shares of the business's stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $53.00, for a total transaction of $554,804.00. Following the transaction, the insider now owns 30 shares in the company, valued at $1,590. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Joseph Shulman sold 10,468 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $53.00, for a total transaction of $554,804.00. Following the sale, the insider now owns 30 shares in the company, valued at $1,590. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, insider Pamela J. Cramer sold 1,395 shares of the company's stock in a transaction on Monday, July 29th. The shares were sold at an average price of $49.06, for a total transaction of $68,438.70. Following the completion of the transaction, the insider now owns 31,735 shares of the company's stock, valued at $1,556,919.10. The disclosure for this sale can be found here. In the last three months, insiders sold 66,182 shares of company stock worth $3,101,567. Corporate insiders own 5.60% of the company's stock.</p>
<div class="lb-trans"><p>根据其他 Rhythm Pharmaceuticals 的消息，内部人员 Joseph Shulman 于 7 月 16 日星期二出售了 10,468 股公司股票。这些股票的平均价格为 53.00 美元，总交易额为 554,804.00 美元。交易完成后，该内部人员在公司持有 30 股，价值 1,590 美元。该交易已在 SEC 的法律文件中披露，可在 SEC 网站上找到。此外，内部人员 Joseph Shulman 于 7 月 16 日星期二又以每股 53.00 美元的平均价格出售了 10,468 股 Rhythm Pharmaceuticals 股票，总交易额为 554,804.00 美元。交易完成后，该内部人员在公司持有 30 股，价值 1,590 美元。该交易已在证券交易委员会的法律文件中披露，可在 SEC 网站上找到。此外，内部人员 Pamela J. Cramer 于 7 月 29 日星期一以每股 49.06 美元的平均价格出售了公司股票 1,395 股，总交易额为 68,438.70 美元。交易完成后，该内部人员在公司持有 31,735 股公司股票，价值 1,556,919.10 美元。过去三个月，内部人员共出售了价值 3,101,567 美元的 66182 股公司股票。公司内部人员持有公司股票的比例为 5.60%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的观点</h2>
</div><p>Several analysts have commented on the stock. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $55.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 7th. Wells Fargo &amp; Company dropped their target price on Rhythm Pharmaceuticals from $53.00 to $52.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, April 18th. Bank of America lowered Rhythm Pharmaceuticals from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their price target for the stock from $49.00 to $42.00 in a research note on Wednesday, May 8th. Finally, Canaccord Genuity Group dropped their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $79.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $55.83.</p>
<div class="lb-trans"><p>一些分析师对该股发表了评论。Needham &amp; Company LLC 在 8 月 7 日星期三的研究报告中重申了对 Rhythm Pharmaceuticals 股票的 “买入” 评级，并给出了 55.00 美元的目标价。富国银行在 4 月 18 日星期四的研究报告中将 Rhythm Pharmaceuticals 的目标价从 53.00 美元降至 52.00 美元，并给予该公司 “超重” 评级。美国银行将 Rhythm Pharmaceuticals 的评级从 “买入” 调降至 “中性”，并将股票的价格目标从 49.00 美元降至 42.00 美元。最后，Canaccord Genuity Group 将 Rhythm Pharmaceuticals 的目标股价从 80.00 美元降至 79.00 美元，并给予该公司 “买入” 评级。一位研究分析师对该股给予持有评级，五位分析师给予买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “中等买入”，共识目标股价为 55.83 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on RYTM</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 RYTM 的最新研究报告</strong></p>
</div><h2>Rhythm Pharmaceuticals Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 公司简介（免费报告）</h2>
</div><p>Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc.是一家专注于罕见神经内分泌疾病的商业阶段生物制药公司。该公司的主力产品候选药是 IMCIVREE（setmelanotide），用于治疗 POMC、PCSK1、LEPR 缺陷性肥胖以及 Bardet-Biedl 综合征和 Alström 综合征。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Michael Burry's Alibaba Bet and the Broader Market Implications</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Jeff Brown's Exegesis AI Stock Picks</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比 Rhythm Pharmaceuticals 更喜欢的股票</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>迈克尔·伯里的阿里巴巴赌注及更广泛的市场影响</li>
<li>如何投资 FAANG 股票</li>
<li>杰夫·布朗的 Exegesis AI 股票推荐</li>
<li>对投资者最重要的沃伦·巴菲特股票：他自己的</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔·哈撒韦购买了奥尔特股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ The 2024 Tech Panic: What Billionaires Know That You Don’t (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 2024 年的科技恐慌：亿万富翁知道的你不知道的（来自 InvestorPlace）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9179&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Rhythm Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买 Rhythm Pharmaceuticals？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rhythm Pharmaceuticals 之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Rhythm Pharmaceuticals 并不在其中。</p>
</div><p>While Rhythm Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Rhythm Pharmaceuticals 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

SG Americas Securities LLC 增持 Rhythm Pharma, Inc. (纳斯达克:RYTM) 的股份